Abstract
ObjectivesReal-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have